The Journal of Allergy and Clinical Immunology
Volume 102, Issue 6 , Pages 935-942 , December 1998

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction

References 

  1. Smith LJ, Glass M, Minkwitz MC. Inhibition of leukotriene D4 -induced bronchoconstriction in subjects with asthma: a concentration-effect study of ICI 204,219. Clin Pharmacol Ther. 1993;54:430–436
  2. Spector SL, Smith LJ, Glass M, Accolate™ Asthma Trialists Group . Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med. 1994;150:618–623
  3. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM, et al.  Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. Clin Ther. 1997;19:675–690
  4. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76–83
  5. Israel E, Cohn J, Dubé L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial. JAMA. 1996;275:931–936
  6. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet L-P, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med. 1995;151:66–70
  7. American Thoracic Society . Standardization of spirometry, 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136
  8. Brown HK, Kempton RA. The application of REML in clinical trials. Stat Med. 1994;13:1601–1617
  9. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol. 1994;47:81–87
  10. Donnelly AL, Glass M, Minkwitz MC, Casale TB. The leukotriene D4 -receptor antagonist, ICI 204,219 relieved symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med. 1995;151:1734–1739
  11. Knapp HR. Reduced allergen-induced nasal congestion in leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med. 1990;323:1745–1748
  12. Henderson WR. Role of leukotrienes in asthma. Ann Allergy. 1994;72:272–278
  13. Okuda M, Watase T, Mezawa A, Lui CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy. 1988;60:537–540
  14. Lydick E, Epstein RS. Interpretation of quality of life changes. Qual Life Res. 1993;2:221–226
  15. Juniper EJ. Quality of life questionnaires: Does statistically significant = clinically important?. J Allergy Clin Immunol. 1998;102:16–17
  16. Reiss TF, Chervinsky P, Dockhorn R, Shingo S, Seidenberg B, Edwards TB, et al.  Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. Arch Intern Med. 1998;158:1213–1220
  17. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS. Interpreting treatment effects in randomised trials. Br Med J. 1998;316:690–693
  18. McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126:712–720
  19. Underwood DC, Osborn RR, Newsholme SJ, Torphy TJ, Hay DWP. Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig: modulation by the LTD4 receptor antagonist, pranlukast, or an interleukin-5 monoclonal antibody. Am J Respir Crit Care Med. 1996;154:850–857
  20. Muñoz NM, Douglas I, Mayer D, Herrnreiter A, Zhu X, Leff AR. Eosinophil chemotaxis inhibited by 5-lipoxygenase blockade and leukotriene receptor antagonism. Am J Respir Crit Care Med. 1997;155:1398–1403
  21. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy. 1995;25:820–827
  22. National Asthma Education Prevention Program . Expert Panel Report II: Guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health; 1997; NIH Publication No: 97-4051

☆ From a Asthma & Allergy Associates, PC, Colorado Springs; b Bernstein Clinical Research Center, Cincinnati; c UMDNJ-New Jersey Medical School, Newark; d Zeneca Pharmaceuticals, Wilmington; e University of Pittsburgh, Pittsburgh; f Asthma & Allergy Research Center, Orange; g Allergy & Asthma Medical Group & Research Center, PC, San Diego; h Asthma & Allergy Research Associates, Inc, Normal; i Thomas Jefferson University, Philadelphia; j University Hospital of Cleveland, Cleveland; k Princeton Allergy & Asthma Associates, PA, Princeton; l Allergy Research Foundation, Inc, Los Angeles; and m Northwest Asthma & Allergy Center, Mount Vernon.

☆☆ *The members of the ACCOLATE Trialists Group are listed in the acknowledgments section.

★ Supported by a grant from Zeneca Pharmaceuticals, Wilmington, Del.

★★ Reprints requests: Robert A. Nathan, MD, Asthma & Allergy Associates, PC, 2709 North Tejon, Colorado Springs, CO 80907.

♢ 0091-6749/98 $5.00 + 0 1/1/93582

PII: S0091-6749(98)70331-8

The Journal of Allergy and Clinical Immunology
Volume 102, Issue 6 , Pages 935-942 , December 1998

Article Tools

* Image Usage & Resolution